AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05787587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous Infusion
Study NCT06230510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introduction of Milk Type
Description: Beginning at approximately age 2, milk (equivalent to 2 cups/day) will be provided at no cost to the family for one year.
Study NCT06230510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Nutrition Counseling
Description: Parent/caregivers will receive quarterly phone-based counseling by a Registered Dietitian (RD) on how to introduce the toddler to the assigned milk and the importance of continuing to drink the assigned milk for the one year.
Study NCT06263673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg once daily, oral
Study NCT06263673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral. Looks similar to the study drug, but it contains no active ingredient.
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT05247957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK cells
Description: NKG2DL-specific CAR-NK cells, 2 infusions on Day 0 and Day 7
Study NCT06220864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNV1521
Description: SNV1521 is a tablet taken orally. Dose and frequency are dependent upon treatment arm.
Study NCT05031338 — intervention group
Intervention type: DEVICE
Intervention: Carpal Tunnel Release
Description: Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the SX-One MicroKnife with ultrasound guidance.
Study NCT05031338 — intervention group
Intervention type: PROCEDURE
Intervention: Carpal Tunnel Release
Description: Carpal Tunnel Release surgery involves transecting the transverse carpal ligament (TCL) in order to reduce median nerve compression and alleviate symptoms. The carpal tunnel release surgery will be performed using the traditional mini-open technique without ultrasound guidance.
Study NCT05315674 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frequent assessment of biomarker panel
Description: During the eight-week inpatient follow-up period there will be daily follow-up of respiratory symptoms, vitals and spirometry, and a thrice weekly collection of spontaneous sputum, nasal swabs and venous blood. These assessments will be repeated at acute worsening of respiratory symptoms at which a stool sample will also be collected.
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06388096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pattern Electroretinogram
Description: Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
Study NCT06388096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pattern Electroretinogram
Description: Non-invasive recording of retinal potentials from a modulating pattern stimulus viewed on a visual display and recorded from surface electrodes around the eye.
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT04990063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy drug
Study NCT04990063 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive TKC transfer therapy
Description: TKC: co-cultured autologous NK cells and γδT cells
Study NCT05486325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endolumik Gastric Calibration Tube (EGCT)
Description: Up to twenty participants will undergo laparoscopic or robotic sleeve gastrectomy using the EGCT. This operation will take approximately 60 minutes.~The portions of the sleeve gastrectomy operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric sleeve~* To perform the leak test of the gastric sleeve Up to ten participants will undergo laparoscopic gastric bypass using the EGCT. This operation will take approximately 120 minutes.~The portions of the gastric bypass operation where the EGCT will be used include:~* To evacuate gastric contents~* During construction of the gastric pouch~* To calibrate closure of the gastrojejunal anastomosis~* To perform a leak test of the gastrojejunal anastomosis In both procedures, The amount of time the EGCT will be inside the patient is approximately 20 minutes. The device is removed prior to the conclusion of the operation, while the patient is under anesthesia.
Study NCT05979220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib combined with Letrozole
Description: A multicenter, single arm, prospective Phase II clinical study
Study NCT05723731 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: taVNS
Description: Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)
Study NCT05723731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: Patients will receive taVNS (device produced by Xi'an Bashui Health Technology Co., Ltd) thirty minutes twice a day in the morning and the night for four weeks (duty circle: 30s on periods and 30s off periods; frequency: 25 Hz; amplitude of 0-2 mA at the maximum level that the patient could tolerate; pulse width: 0.5ms)
Study NCT05723731 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Laxative Agent
Description: Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
Study NCT05723731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laxative Agent
Description: Bisacodyl or glycerin enemas can be used in patients who do not have a bowel movement for more than 3 days.
Study NCT03924063 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hemiverse
Description: Implantation of the hemiverse shoulderprothesis
Study NCT05557604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl
Description: STAD androgen deprivation
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT06064669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin pretreatment before ovarian stimulation
Description: The enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
Study NCT06064669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pretreatment before ovarian stimulation
Description: The enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks prior to ovarian stimulation till oocyte retrieval.
Study NCT06064669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin pretreatment before endometrial preparation for frozen embryo transfer
Description: After oocyte retrieval, the enrolled patients will be prescribed metformin 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
Study NCT06064669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pretreatment before endometrial preparation for frozen embryo transfer
Description: After oocyte retrieval, the enrolled patients will be prescribed placebo 850mg twice daily for at least 4 weeks before endometrial preparation for frozen embryo transfer and till the establishment of clinical pregnancy (7-8 weeks gestation) after the first frozen embryo transfer.
Study NCT05213312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab, 360mg intravenous infusion (ivgtt.), on DAY1, Q3W for two cycles;
Study NCT05213312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
Study NCT05213312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2 on DAY2 with paclitaxel, Q3W or 80 mg/m2 on DAY1, Q3W ivgtt for two cycles
Study NCT05213312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
Study NCT05213312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 on DAY2, with cisplatin Q3W, ivgtt for two cycles
Study NCT05213312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5Fluorouracil
Description: 800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
Study NCT05213312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 800 mg/m2 on DAYS1-5 with cisplatin, Q3W for two cycles
Study NCT05213312 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophagectomy (minimally invasive)
Description: 4-6 weeks after neoadjuvant therapy.
Study NCT05213312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy (minimally invasive)
Description: 4-6 weeks after neoadjuvant therapy.
Study NCT05655559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnare
Description: Measurement of Dyspnea and Fatigue during submaximal exercise with The Modified Borg Scale (MBS).
Study NCT05655559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Muscle Oxygen Monitor
Description: Measurement of muscle oxygenation with Moxy Muscle Oxygen Monitor.
Study NCT04915118 — intervention group
Intervention type: OTHER
Intervention: Decompensation event
Description: NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
Study NCT04727632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Fluoroestradiol (FES) PET/CT
Description: \[18F\]Fluoroestradiol (FES) PET/CT
Study NCT04233398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Echopulse (HIFU ablation)
Description: High-intensity focused ultrasound (HIFU) is a non-invasive, non-invasive treatment method. The principle is to focus high-intensity ultrasound on the target area. Energy is absorbed by the target tissue and converted into thermal energy. The local temperature quickly reaches a maximum of 85 ° C. It induces coagulative necrosis of focus tissue cells, but does not damage the tissues surrounding the treatment targ
Study NCT04800042 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic test
Description: Blood iron status : ferritin and transferrin saturation factor
Study NCT06043687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice Paste
Description: Scaling and Root planing followed by dentifrice usage
Study NCT06043687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentifrice Paste
Description: Scaling and Root planing followed by dentifrice usage
Study NCT06043687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dentifrice Paste
Description: Scaling and Root planing followed by dentifrice usage
Study NCT06494150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Sirolimus
Description: nab-Sirolimus will be administered by intravenous infusion at 100mg/m2 on days 1 and 8 of each 21-day cycle
Study NCT06494150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered by intramuscular injection at 500mg on days 1 and 15 of cycle 1 and then every 21 days
Study NCT06553118 — intervention group
Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: Patients already admitted for total knee arthroplasty for knee osteoarthritis will have the procedure as planned
Study NCT05761639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: The program will be attended in person in the clinic's cardiac rehabilitation program and consists of physical exercise supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation, for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up. , muscle strengthening of lower and upper limbs, continuous aerobic training and return to calm.
Study NCT05761639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: 1 time a week 30 minutes for each patient individually and in a group with topics: knowledge of the disease, use of medications, warning signs, anxiety management, relaxation techniques, exercises at home, sexual relations and adequate nutrition
Study NCT05761639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: The program will be assisted by virtual technology and consists of physical exercise at home (for 60 minutes, 3 times a week for a period of 12 weeks, structured by warming up, muscle strengthening of lower and upper limbs, continuous aerobic training and cool down ) supervised by a physiotherapist specializing in cardiac and pulmonary rehabilitation through the Google Meet platform
Study NCT05761639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: follow-up
Description: Telephone calls will be made 3 times a week as a follow-up method to obtain information from each person about their heart rate and perception of effort in relation to the activities carried out where they are encouraged to exercise at home on days without intervention.
Study NCT04903951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Servoventilation (ASV) therapy
Description: Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated
Study NCT04903951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best medical treatment
Description: Best medical treatment for stroke, including rehabilitation
Study NCT04903951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Best medical treatment for stroke, including rehabilitation
Study NCT05001217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional medication
Description: Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
Study NCT05001217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medication
Description: Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
Study NCT05001217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine treatment
Description: 1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction
Study NCT04856410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spaceflight
Description: Exposure to the spaceflight environment on the International Space Station for 2, 6, or 12 months.
Study NCT04856410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controls
Description: No intervention
Study NCT05339334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir
Description: PF-07321332/ritonavir will be given by mouth two times a day for 10 days
Study NCT05710224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V181
Description: 0.5 mL SC dose of V181
Study NCT05710224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Butantan-DV
Description: 0.5 mL SC dose of Butantan-DV
Study NCT03516968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly bolus of cholecalciferol per os
Description: Bolus therapy (100'000 - 200'000 IU/month depending on age: \< or ≥ 9 years old) for 3 months
Study NCT03516968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daily dose of cholecalciferol per os
Description: Daily substitution (3'500 to 6'500 IU/day depending on age: \< or ≥ 9 years old) for 3 months
Study NCT03516968 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: no cholecalciferol therapy
Study NCT05917509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/3TC
Description: DTG/3TC FDC will be administered as an oral once daily tablet.
Study NCT05917509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir (CAB) LA
Description: CAB LA will be administered as a gluteal intramuscular injection once every 2 months in combination with RPV LA.
Study NCT05917509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) LA
Description: RPV LA will be administered as a gluteal intramuscular injection once every 2 months in combination with CAB LA.
Study NCT06190613 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combination Peer navigation and mHealth intervention
Description: Peer navigation and SMS text message medication reminders (adapted to YMSM and YTW in community outreach-based delivery approach)
Study NCT05174767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMDS
Description: AMDS Implantation
Study NCT05713383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory Feedback
Description: Sound amplification is used to accentuate participants' footsteps, while asking them to step softly so as to reduce this sound.
Study NCT05788666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GeriKit Mobile Application
Description: Digital health app used for comprehensive geriatric assessment (CGA). The app includes a series of brief, well-validated instruments: the MiniCog, 30-Second Chair Stand, Activities of Daily Living, Instrumental Activities of Daily Living, Patient Health Questionnaire (PHQ-9), Mini Nutrition Assessment, 2-Item Fall Screen, and Polypharmacy screen.
Study NCT04812093 — intervention group
Intervention type: DEVICE
Intervention: Spectroscopic otoscope measurements
Description: Spectroscopic otoscope measurements are taken with the investigational device. Each measurement consists of placing the device in the ear canal and illuminating the ear with multiple light sources in a short period of time. If wax is present in the ear canal, it is removed by the study physician and another measurement is taken.
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mutation Carrier Screening
Description: Undergo tumor mutational screening
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mutation Carrier Screening
Description: Undergo tumor mutational screening
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neratinib Maleate
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib Maleate
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib Hydrochloride Monohydrate
Description: Given PO